- In April 2025, Germany's Merck announced its acquisition of U.S.-based biotech firm SpringWorks Therapeutics for USD3.9 billion. This strategic move aims to bolster Merck's oncology portfolio, particularly in rare tumors, and is expected to enhance the company's presence in the U.S. market
- In March 2024, AstraZeneca agreed to acquire Canadian company Fusion Pharmaceuticals for USD2.4 billion. Fusion specializes in radioconjugates, a next-generation cancer treatment that targets cancer cells with radioactive isotopes, minimizing damage to healthy cells. This acquisition is set to enhance AstraZeneca's oncology pipeline and expand its presence in Canada
- In September 2023, Cardinal Health announced its plan to acquire Integrated Oncology Network for USD1.12 billion. This acquisition is part of Cardinal Health's strategy to expand into the oncology care sector, merging its cancer-focused unit Navista with Integrated Oncology Network's extensive network, which includes over 100 healthcare providers across 10 states and more than 50 practice sites
- In November 2023, AbbVie announced its agreement to acquire ImmunoGen, including its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), for approximately USD10.1 billion. This acquisition is expected to expand AbbVie's solid tumor portfolio and strengthen its position in the oncology market.
- In December 2022, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq), an immunotherapy drug developed by F. Hoffmann-La Roche Ltd., for treating Alveolar Soft Part Sarcoma (ASPS) in adults and children aged 2 and older if the disease has metastasized or is inoperable. This approval marked a significant advancement in cancer supportive care treatments
